1. Home
  2. SDGR vs OGN Comparison

SDGR vs OGN Comparison

Compare SDGR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

N/A

Current Price

$30.46

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Organon & Co.

OGN

Organon & Co.

N/A

Current Price

$13.71

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SDGR
OGN
Founded
1990
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SDGR
OGN
Price
$30.46
$13.71
Analyst Decision
Buy
Hold
Analyst Count
7
5
Target Price
★ $21.43
$11.25
AVG Volume (30 Days)
2.0M
★ 2.1M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
★ 0.58%
EPS Growth
★ 45.14
N/A
EPS
N/A
★ 0.95
Revenue
$255,869,000.00
★ $6,216,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.12
$2.51
P/E Ratio
★ N/A
$14.47
Revenue Growth
★ 23.29
N/A
52 Week Low
$10.95
$5.69
52 Week High
$31.59
$13.79

Technical Indicators

Market Signals
Indicator
SDGR
OGN
Relative Strength Index (RSI) 73.76 53.63
Support Level $11.27 $13.46
Resistance Level $31.59 $13.77
Average True Range (ATR) 2.33 0.03
MACD 0.28 -0.00
Stochastic Oscillator 90.69 62.50

Price Performance

Historical Comparison
SDGR
OGN

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Share on Social Networks: